82 FR 61302 - Agency Information Collection Activities; Submission for OMB Review; Comment Request

FEDERAL TRADE COMMISSION

Federal Register Volume 82, Issue 247 (December 27, 2017)

Page Range		61302-61304
FR Document		2017-27868
In compliance with the Paperwork Reduction Act (PRA) of 1995, the FTC is seeking public comments on its request to OMB for a three- year extension of the current PRA clearance for information collection requirements contained in its Trade Regulation Rule entitled Labeling and Advertising of Home Insulation (R-value Rule or Rule). That clearance expires on January 31, 2018.
Federal Register, Volume 82 Issue 247 (Wednesday, December 27, 2017)
[Federal Register Volume 82, Number 247 (Wednesday, December 27, 2017)]
[Notices]
[Pages 61302-61304]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-27868]


-----------------------------------------------------------------------

FEDERAL TRADE COMMISSION


Agency Information Collection Activities; Submission for OMB 
Review; Comment Request

AGENCY: Federal Trade Commission (``FTC'').

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995, 
the FTC is seeking public comments on its request to OMB for a three-
year extension of the current PRA clearance for information collection 
requirements contained in its Trade Regulation Rule entitled Labeling 
and Advertising of Home Insulation (R-value Rule or Rule). That 
clearance expires on January 31, 2018.

DATES: Comments must be received by January 26, 2018.

ADDRESSES: Interested parties may file a comment online or on paper by 
following the instructions in the Request for Comments part of the 
SUPPLEMENTARY INFORMATION section below. Write ``R-value Rule: FTC File 
No. R811001'' on your comment, and file your comment online at https://ftcpublic.commentworks.com/ftc/rvaluerulepra2 by following the 
instructions on the web-based form. If you prefer to file your comment 
on paper, mail your comment to the following address: Federal Trade 
Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite 
CC-5610 (Annex J), Washington, DC 20580, or deliver your comment to the 
following address: Federal Trade Commission, Office of the Secretary, 
Constitution Center, 400 7th Street SW, 5th Floor, Suite 5610 (Annex 
J), Washington, DC 20024.

[[Page 61303]]


FOR FURTHER INFORMATION CONTACT: Requests for additional information or 
copies of the proposed information requirements should be addressed to 
Hampton Newsome, Attorney, Division of Enforcement, Bureau of Consumer 
Protection, Federal Trade Commission, Mail Code CC-9528, 600 
Pennsylvania Ave. NW, Washington, DC 20580, (202) 326-2889.

SUPPLEMENTARY INFORMATION: 
    Title: R-value Rule, 16 CFR part 460.
    OMB Control Number: 3084-0109.
    Type of Review: Extension of a currently approved collection.
    Abstract: The R-value Rule establishes uniform standards for the 
substantiation and disclosure of accurate, material product information 
about the thermal performance characteristics of home insulation 
products. The R-value of an insulation signifies the insulation's 
degree of resistance to the flow of heat. This information tells 
consumers how well a product is likely to perform as an insulator and 
allows consumers to determine whether the cost of the insulation is 
justified.
    On October 11, 2017, the Commission sought comment on the 
information collection requirements in the R-value Rule. 82 FR 47207. 
No germane comments were received. As required by OMB regulations, 5 
CFR part 1320, the FTC is providing this second opportunity for public 
comment. Comments should address only the information collection 
requirements of the current Rule. They should not address proposed Rule 
amendments recently announced by the Commission in a separate 
proceeding.\1\
---------------------------------------------------------------------------

    \1\ See, ``FTC Proposes Updates to R-Value Rule for Home 
Insulation Products,'' Dec. 4, 2017, https://www.ftc.gov/news-events/press-releases/2017/12/ftc-proposes-updates-r-value-rule-home-insulation-products.
---------------------------------------------------------------------------

    Estimated Annual Hours Burden: 131,740 hours.
    Likely Respondents and Estimated Burden:
    Installation manufacturers, installers, new home builders/sellers, 
dealers and retailers.
    (a) Installation manufacturers.
     Testing by installation manufacturers - 15 new products/
year x 2 hours each = 30 hours; and
     Disclosures by installation manufacturers - [(144 
manufacturers x 20 hours) + (6 largest manufacturers x 80 hours each] = 
3,360 hours.
     Recordkeeping by installation manufacturers - 150 
manufacturers x 1 hour each = 150 hours.
    (b) Installers.
     Disclosures by retrofit installers (manufacturer's 
insulation fact sheet) - 2 million retrofit installations/year x 2 
minutes each = 66,667 hours.
     Disclosures by installers (advertising) - 1,615 installers 
x 1 hour each = 1,615 hours.
     Recordkeeping by installers - 1,615 installers x 5 minutes 
each = 135 hours.
    (c) New home builders/sellers, dealers.
     Disclosures by new home sellers - 1,174,000 new home 
sales/year x 30 seconds each = 9,783 hours.
    (d) Retailers.
     Disclosures by retailers - [25,000 retailers x 1 hour each 
(fact sheets) + 25,000 retailers x 1 hour each (advertising disclosure) 
= 50,000 hours.
    Frequency of Response: Periodic.
    Total Annual Labor Cost: $2,616,943 per year (solely related to 
labor costs) [approximately $858 for testing, based on 30 hours for 
manufacturers (30 hours x $28.61 per hour for skilled technical 
personnel); $4,284 for manufacturers' and installers' compliance with 
the Rule's recordkeeping requirements, based on 285 hours (285 hours x 
$15.03 per hour for clerical personnel); $50,501 for manufacturers' 
compliance with third-party disclosure requirements, based on 3,360 
hours (3,360 hours x $15.03 per hour for clerical personnel); and 
$2,561,300 for disclosure compliance by installers, new home sellers, 
and retailers (128,065 hours x $20 per hour for sales persons).]

Request for Comment

    You can file a comment online or on paper. For the FTC to consider 
your comment, we must receive it on or before January 26, 2018. Write 
``R-value Rule: FTC File No. R811001'' on your comment. Your comment--
including your name and your state--will be placed on the public record 
of this proceeding, including, to the extent practicable, on the public 
Commission website, at http://www.ftc.gov/os/publiccomments.shtm. As a 
matter of discretion, the Commission tries to remove individuals' home 
contact information from comments before placing them on the Commission 
website.
    Postal mail addressed to the Commission is subject to delay due to 
heightened security screening. As a result, we encourage you to submit 
your comments online, or to send them to the Commission by courier or 
overnight service. To make sure that the Commission considers your 
online comment, you must file it at https://ftcpublic.commentworks.com/ftc/rvaluerulepra2 by following the instructions on the web-based form. 
When this Notice appears at http://www.regulations.gov, you also may 
file a comment through that website.
    If you file your comment on paper, write ``R-value Rule: FTC File 
No. R811001'' on your comment and on the envelope, and mail it to the 
following address: Federal Trade Commission, Office of the Secretary, 
600 Pennsylvania Avenue NW, Suite CC-5610 (Annex J), Washington, DC 
20580, or deliver your comment to the following address: Federal Trade 
Commission, Office of the Secretary, Constitution Center, 400 7th 
Street SW, 5th Floor, Suite 5610, Washington, DC 20024. If possible, 
submit your paper comment to the Commission by courier or overnight 
service.
    Comments on the information collection requirements subject to 
review under the PRA should additionally be submitted to OMB. If sent 
by U.S. mail, they should be addressed to Office of Information and 
Regulatory Affairs, Office of Management and Budget, Attention: Desk 
Officer for the Federal Trade Commission, New Executive Office 
Building, Docket Library, Room 10102, 725 17th Street NW, Washington, 
DC 20503. Comments sent to OMB by U.S. postal mail are subject to 
delays due to heightened security precautions. Thus, comments can also 
be sent via email to [email protected].
    Because your comment will be placed on the publicly accessible FTC 
website at https://www.ftc.gov, you are solely responsible for making 
sure that your comment does not include any sensitive or confidential 
information. In particular, your comment should not include any 
sensitive personal information, such as your or anyone else's Social 
Security number; date of birth; driver's license number or other state 
identification number, or foreign country equivalent; passport number; 
financial account number; or credit or debit card number. You are also 
solely responsible for making sure that your comment does not include 
any sensitive health information, such as medical records or other 
individually identifiable health information. In addition, your comment 
should not include any ``trade secret or any commercial or financial 
information which . . . is privileged or confidential'' --as provided 
by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 
4.10(a)(2), 16 CFR 4.10(a)(2)--including in particular competitively 
sensitive information such as costs, sales statistics, inventories, 
formulas, patterns, devices, manufacturing processes, or customer 
names.
    Comments containing material for which confidential treatment is

[[Page 61304]]

requested must be filed in paper form, must be clearly labeled 
``Confidential,'' and must comply with FTC Rule 4.9(c). In particular, 
the written request for confidential treatment that accompanies the 
comment must include the factual and legal basis for the request, and 
must identify the specific portions of the comment to be withheld from 
the public record. See FTC Rule 4.9(c). Your comment will be kept 
confidential only if the General Counsel grants your request in 
accordance with the law and the public interest. Once your comment has 
been posted on the public FTC website--as legally required by FTC Rule 
4.9(b)--we cannot redact or remove your comment from the FTC website, 
unless you submit a confidentiality request that meets the requirements 
for such treatment under FTC Rule 4.9(c), and the General Counsel 
grants that request.
    The FTC Act and other laws that the Commission administers permit 
the collection of public comments to consider and use in this 
proceeding as appropriate. The Commission will consider all timely and 
responsive public comments that it receives on or before January 26, 
2018. For information on the Commission's privacy policy, including 
routine uses permitted by the Privacy Act, see https://www.ftc.gov/site-information/privacy-policy.

David C. Shonka,
Acting General Counsel.
[FR Doc. 2017-27868 Filed 12-26-17; 8:45 am]
 BILLING CODE 6750-01-P
61304 Federal Register / Vol. 82, No. 247 / Wednesday, December 27, 2017 / Notices

requested must be filed in paper form, relinquish its status as a PSO for any a PSO’s listing expires. Section 3.108(d)
must be clearly labeled ‘‘Confidential,’’ reason, or when a PSO’s listing expires. of the Patient Safety Rule requires
and must comply with FTC Rule 4.9(c). AHRQ has accepted a notification of AHRQ to provide public notice when it
In particular, the written request for voluntary relinquishment from the removes an organization from the list of
confidential treatment that accompanies Regenstrief Center for Healthcare federally approved PSOs.
the comment must include the factual Engineering at Purdue University AHRQ has accepted a notification
and legal basis for the request, and must Patient Safety Organization (RCHE from RCHE Purdue PSO, a component
identify the specific portions of the Purdue PSO) of its status as a PSO, and entity of Purdue University, PSO
comment to be withheld from the public has delisted the PSO accordingly. number P0168, to voluntarily relinquish
record. See FTC Rule 4.9(c). Your DATES: The directories for both listed its status as a PSO. Accordingly, RCHE
comment will be kept confidential only and delisted PSOs are ongoing and Purdue PSO was delisted effective at
if the General Counsel grants your reviewed weekly by AHRQ. The 12:00 Midnight ET (2400) on December
request in accordance with the law and delisting was effective at 12:00 Midnight 15, 2017.
the public interest. Once your comment ET (2400) on December 15, 2017. More information on PSOs can be
has been posted on the public FTC ADDRESSES: Both directories can be obtained through AHRQ’s PSO website
website—as legally required by FTC accessed electronically at the following at http://www.pso.ahrq.gov.
Rule 4.9(b)—we cannot redact or HHS website: http://www.pso.ahrq.gov/
remove your comment from the FTC Sharon B. Arnold,
listed. Deputy Director.
website, unless you submit a
FOR FURTHER INFORMATION CONTACT:
confidentiality request that meets the [FR Doc. 2017–27803 Filed 12–26–17; 8:45 am]
requirements for such treatment under Eileen Hogan, Center for Quality BILLING CODE 4160–90–P
FTC Rule 4.9(c), and the General Improvement and Patient Safety, AHRQ,
Counsel grants that request. 5600 Fishers Lane, Room 06N94B,
The FTC Act and other laws that the Rockville, MD 20857; Telephone (toll DEPARTMENT OF HEALTH AND
Commission administers permit the free): (866) 403–3697; Telephone (local): HUMAN SERVICES
collection of public comments to (301) 427–1111; TTY (toll free): (866)
consider and use in this proceeding as 438–7231; TTY (local): (301) 427–1130; Food and Drug Administration
appropriate. The Commission will Email: pso@ahrq.hhs.gov.
consider all timely and responsive SUPPLEMENTARY INFORMATION: [Docket No. FDA–2017–D–6784]
public comments that it receives on or Background
before January 26, 2018. For information Implementation of Pathogen Reduction
on the Commission’s privacy policy, The Patient Safety and Quality Technology in the Manufacture of
including routine uses permitted by the Improvement Act of 2005, 42 U.S.C. Blood Components in Blood
Privacy Act, see https://www.ftc.gov/ 299b–21 to b–26, (Patient Safety Act) Establishments: Questions and
site-information/privacy-policy. and the related Patient Safety and Answers; Draft Guidance for Industry;
Quality Improvement Final Rule, 42 Availability
David C. Shonka, CFR part 3 (Patient Safety Rule),
Acting General Counsel. published in the Federal Register on AGENCY: Food and Drug Administration,
[FR Doc. 2017–27868 Filed 12–26–17; 8:45 am] November 21, 2008, 73 FR 70732– HHS.
BILLING CODE 6750–01–P 70814, establish a framework by which ACTION: Notice of availability.
hospitals, doctors, and other health care
providers may voluntarily report SUMMARY: The Food and Drug
DEPARTMENT OF HEALTH AND information to Patient Safety Administration (FDA or Agency) is
HUMAN SERVICES Organizations (PSOs), on a privileged announcing the availability of a draft
and confidential basis, for the document entitled ‘‘Implementation of
Agency for Healthcare Research and aggregation and analysis of patient Pathogen Reduction Technology in the
Quality safety events. Manufacture of Blood Components in
The Patient Safety Act authorizes the Blood Establishments: Questions and
Patient Safety Organizations: listing of PSOs, which are entities or Answers; Draft Guidance for Industry.’’
Voluntary Relinquishment From the component organizations whose The draft guidance document provides
Regenstrief Center for Healthcare mission and primary activity are to blood establishments that collect or
Engineering at Purdue University conduct activities to improve patient process blood and blood components
Patient Safety Organization (RCHE safety and the quality of health care with recommendations for
Purdue PSO) delivery. implementing pathogen reduction
HHS issued the Patient Safety Rule to technology in the manufacture of
AGENCY: Agency for Healthcare Research
implement the Patient Safety Act. pathogen-reduced blood components.
and Quality (AHRQ), Department of
AHRQ administers the provisions of the The guidance also provides answers to
Health and Human Services (HHS).
Patient Safety Act and Patient Safety frequently asked questions concerning
ACTION: Notice of delisting.
Rule relating to the listing and operation the implementation of the INTERCEPT®
SUMMARY: The Patient Safety Rule of PSOs. The Patient Safety Rule Blood System for Platelets and Plasma.
authorizes AHRQ, on behalf of the authorizes AHRQ to list as a PSO an The recommendations apply to licensed
Secretary of HHS, to list as a PSO an entity that attests that it meets the blood establishments that intend to
daltland on DSKBBV9HB2PROD with NOTICES

entity that attests that it meets the statutory and regulatory requirements manufacture pathogen-reduced blood
statutory and regulatory requirements for listing. A PSO can be ‘‘delisted’’ if components using an FDA approved
for listing. A PSO can be ‘‘delisted’’ by it is found to no longer meet the pathogen reduction device.
the Secretary if it is found to no longer requirements of the Patient Safety Act DATES: Submit either electronic or
meet the requirements of the Patient and Patient Safety Rule, when a PSO written comments on the draft guidance
Safety Act and Patient Safety Rule, chooses to voluntarily relinquish its by March 27, 2018 to ensure that the
when a PSO chooses to voluntarily status as a PSO for any reason, or when Agency considers your comment on this

VerDate Sep<11>2014 21:43 Dec 26, 2017 Jkt 244001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\27DEN1.SGM 27DEN1
Document Created: 2017-12-27 02:23:39
Document Modified: 2017-12-27 02:23:39
Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice and request for comment.
Dates		Comments must be received by January 26, 2018.
Contact		Requests for additional information or
FR Citation		82 FR 61302